Pharmacokinetics and Molecular Modeling Indicate nAChRα4-Derived Peptide HAEE Goes through the Blood–Brain Barrier

Pharmacokinetics and Molecular Modeling Indicate nAChRα4-Derived Peptide HAEE Goes through the Blood–Brain Barrier

One of the treatment strategies for Alzheimer’s disease (AD) is based on the use of pharmacological agents capable of binding to beta-amyloid (Aβ) and blocking its aggregation in the brain. Previously, we found that intravenous administration of the synthetic tetrapeptide Acetyl-His-Ala-Glu-Glu-Amid...

Full description

Bibliographic Details
Main Authors: Yurii A. Zolotarev, Vladimir A. Mitkevich, Stanislav I. Shram, Alexei A. Adzhubei, Anna P. Tolstova, Oleg B. Talibov, Alexander K. Dadayan, Nikolai F. Myasoyedov, Alexander A. Makarov, Sergey A. Kozin
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Biomolecules
Subjects:
Alzheimer’s disease
beta-amyloid
α4β2 nicotinic acetylcholine receptor
peptide drug
blood–brain barrier
receptor-mediated transcytosis
Online Access:https://www.mdpi.com/2218-273X/11/6/909

Internet

https://www.mdpi.com/2218-273X/11/6/909

Similar Items